CD28/CTLA-4 and CD80/CD86 families

Immunologic Research

Volumn 19, Issue 1, 1999, Pages 1-24

  Slavik, Jacqueline M ^a   Hutchcroft, Jill E ^a,d   Bierer, Barbara E ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Cell surface molecules; Costimulatory molecules; Signal transduction; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MEMBRANE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; CELL DEATH; CLONAL ANERGY; CONTROLLED STUDY; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0033062691     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786473     Document Type: Review

References (198)

1. Bretscher P: The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 1992;13:74-76.
2. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-1068.
3. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
4. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 1994;15(7):321-332.
5. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993;11:191-212.
6. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser GW, et al.: SH2 domains recognize specific phosphopeptide sequences. Cell 1993;72:767-778.
7. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-614.
8. Cobb MH, Hepler HE, Cheng M, Robbins D: The mitogen-activated protein kinases Erk1 and Erk2. Scm Cancer Biol 1994;5:261-268.
9. Parry RV, Olive D, Westwick J, Sansom DM, Ward SG: Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory receptor CD28. Biochem J 1997;326:249-257.
10. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;793-801.
11. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, et al.: CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 1992;149(12):3795-3801.
12. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, et al.: Coexpression and functional cooperativity of CTLA-4 and CD28 mRNA on activated T lymphocytes. J Exp Med 1992;176:1595-1604.
13. Brunet J-F, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei M-G, Golstein P: A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987;328:267-270.
14. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al.: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
15. Schneider H, Prasad KVS, Shoelson SE, Rudd CE: CTLA-4 binding to the lipid kinase phosphatidylinositol 3-Kinase in T cells. J Exp Med 1995;181:351-355.
16. Leung HT, Bradshaw J, Cleaveland JS, Linsley PS: Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995;270:25,107-25,114.
17. Alegre M, Noel PJ, Eisfelder BJ, Chuang E, Clark M, Reiner SL, et al.: Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996;157:4762-4770.
18. Shiratori T, Miyatake S, Ohno H, Nakadeko C, Isono K, Bonifacino JS, et al.: Tyrosine phosphorylation controls internaliztion of CTLA-4 by regulating its interaction with clathrin-associated adapter complex AP-2. Immunity 1997;6:583-589.
19. Zhang Y, Allison JP: Interaction of CTLA-4 with AP50, a clathrin-coated pit adapter protein. Proc Natl Acad Sci USA 1997;94:9273-9278.
20. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS: Intracellular trafficking of CTLA-4 and localization towards sites of TcR engagement. Immunity 1996; 4:535-543.
21. Yokochi T, Holly RD, Clark EA: B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblstoid cell lines, and Burkitt's lymphomas. J Immunol 1982;128(2):823-828.
22. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990;87:5031-5035.
23. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler L: B7, a new member of the 1g superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989;143:2714-2722.
24. Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou, L-J, Whiite M, et al.: Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991;174(3):625-631.
25. Doty RT, Clark EA: Two regions in the CD80 cytoplasmic tail regulate CD80 redistribution and T cell costimulation. J Immunol 1998;161:2700-2707.
26. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, et al.: Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 1996;271(43):26,762-26,771.
27. Doty RT, Clark EA: Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation. J Immunol 1996;157:3270-3279.
28. Chen C, Gault A, Shen L, Nabavi N: Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. J Immunol 1994; 152:4929-4936.
29. Freeman GJ, Boriello F, Hodes RJ, Resier H, Gribben JG, Ng JW, et al.: Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 1993;178:2185-2192.
30. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Jur. VAR, Lombard LA, et al.: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
31. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 sytem of T cell costimulation. Ann Rev Immunol 1996;14:233-258.
32. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, et al.: B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-79.
33. Lenschow DJ, Su GH-T, Zuckerman LA, Nabavi N, Jellis CL, Gray G, et al.: Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA 1993;90:11,054-11,058.
34. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ: Comparative analysis of B7-1 and B7-2 costimulatory ligands:expression and function. J Exp Med 1994;180:631-641.
35. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray, GS, Nadler LM.: Activated human B lymphocytes express three CTLA4 binding counter-receptors which costimulate T cell activation. Prove Natl Acad Sci USA 1993;90:11,059-11,063.
36. Ho WY, Cooke MP, Goodnow CC, Davis MM: Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J Exp Med 1995;179:1539-1549.
37. Ranheim EA,Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925.
38. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R: Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 1995;25:596-603.
39. Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, et al.: The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) its well its B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol 1998;161:2708-2715.
40. Valle A, Aubry JP, Durnad I, Bancheraue J: IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: An amplification mechanism for T-B interactions. Int Immunol 1991;2:229-235.
41. Stack RM, Lenschlow DJ, Gray GS, Bluestone JA, Fitch FW: IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol 1994;152:5723-5733.
42. Bulens C, Willems F, Delvaux A, Picrard G, Delville J-P, Velu T, et al.: Interleukin 10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995;25:2421-2426.
43. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, et al.: Interleukin 10 inhibits B7 and ICAM-1 expression on human monocytes. Eur J Immunol 1994;24:1007-1009.
44. Truneh A, Reddy M, Ryan P, Lyn SD, Eichman C, Couez D, et al.: Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2):analysis by site directed mutagenesis. Mol Immunol 1996;33(3):321-334.
45. Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, et al.: Both extracellular immunoglobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J Biol Chem 1996;270:21181-21187.
46. Kariv I, Truneh A, Sweet R: Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. J Immunol 1996: 29-38.
47. Ellis JH, Burden MN, Vinogradov DV, Linge C, Crowe JS: Interactions of CD80 and CD86 with CD28 and CTLA-4. J Immunol 1996:2700-2709.
48. Fargeas CA, Truneh A, Reddy M, Hurle M, Sweet R, Sekaly R-P: Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA-4. J Exp Med 1995;182:667-675.
49. Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J, et al.: Complementarity determining region 1 (CDR1)- and CDR3-analagous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994;180:2049-2058.
50. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, et al.: Differential T cell costimulatory requirements in CD28 deficient mice. Science 1993;261:609-612.
51. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, et al.: Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994;1:501-508.
52. Freeman GJ, Borriello R, Hodes RJ, Reiser H, S. HK, Laszlo G, et al.: Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993;262:907-909.
53. Borrielo F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, et al.: B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 1997:303-313.
54. Schweitzer AN, Sharpe AH: Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol 1998;161:2762-2771.
55. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB: T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987;7(12):4472-4481.
56. Alberola-Ila J, Takaki S, Kerner JD, Perlmutter RM: Differential signaling by lymphocyte antigen receptors. Ann Rev Immunol 1997;15:125-154.
57. Allison JP: CD28-B7 interactions in T-cell activation. Curr Opinion Immunol 1994;6:414-419.
58. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555-559.
59. Cantrell D: T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996;14:259-574.
60. Ashwell JD, Klausner RD: Genetic and mutational analysis of the T cell antigen receptor. Ann Rev Immunol 1990;8:139-167.
61. Clevers H, Alarcon B, Wileman T, Terhorst C: The T cell receptor/CD3 complex: A dynamic protein ensemble. Ann Rev Immunol 1988;6:629-662.
62. Reth M: Antigen receptor tail clue. Nature 1989;338:383-384.
63. Baniyash M, Garcia-Morales P, Luong E, Samelson LE, Klausner RD: The T cell receptor ζ chain is tyrosine phosphorylated upon activation. J Biol Chem 1988;263:9874-9878.
64. Alberola-Ila J, Places L, de la Calle O, Romero M, Yagüe J, Gallart T, et al.: Stimulation through the TCR/CD3 complex up-regulates the CD2 surface expression on human T-lymphocytes. J Immunol 1991;146:1085-1092.
65. Chan AC, Iwashima M, Turck CW, Weiss A: ZAP-70: A 70 kD protein-tyrosine that associates with the TCR ζ chain. Cell 1992;71:649-662.
66. Granja C, kin L, Yunis EJ, Relias V, DasGupta JD. PLCγ1: A possible mediator of T cell receptor function. J Biol Chem 1991;266:16,277-16,280.
67. Secrist JP, Karnitz L, Abraham RT. T-cell antigen receptor ligation induces tyrosine phosphorylation of phospholipase C-γ1. J Biol Chem 1991;266:12,135.
68. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-274.
69. Park DJ, Rho HW, Rhee SG: CD3 stimulation causes phosphorylation of phospholipase Cγ1 on serine and tyrosine residues in a human T cell line. Proc Natl Acad Sci USA 1991;88:5453-5457.
70. ras in T cells. Immunol Today 1992;13(3):89-92.
71. Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW: Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 1994;93:2134-2140.
72. McKormick F: How receptors turn Ras on. Nature 1993;363:15,16.
73. Ravichandran KS, Lee KK, Zhou SY, Cantley LC, Burn P, Burakoff SJ: Interaction of SHC with the zeta-chain of the T-cell receptor upon T-cell activation. Science 1993;262:902-905.
74. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opinion Cell Biol 1997;9:180-186.
75. Ip YT, Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr Opinion Cell Biol 1998;10:205-219.
76. Cano E, Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995;20:117-122.
77. Genot E, Cleverley S, Henning S, Cantrell D: Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J 1996;15:3923-3933.
78. Fields PE, Gajewski TF, Fitch FW: Blocked Ras activation in anergic CD4+ T cells. Science 1996;271:1276-1278.
79. DeSilva DR, Jones EA, Favata MF, Jaffee BD, Magolda RL, Trzaskos JM, et al.: Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol 1998;160:4175-4181.
80. Crespo P, Bustelo XR, Aaronson DS, Coso OA, Lopez-Barahona M, Barbacid M, et al.: Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene 1996;13:455-460.
81. Vojtek AB, Cooper JA: Rho family members: Activators of MAPK cascades. Cell 1995;82:527-529.
82. Enslen H, Raingeaud J, Davis RJ: Selective Activation of p38 Mitogen-activated (MAP) kinase isoforms by the MAPK kinases MKK3 and MKK6. J Biol Chem 1998;273(3):1741-1748.
83. Han J, Lee, JD, Jiang Y, Li Z, Feng L, Ulevitch RJ: Characterization of the structure and function of a novel MAPK kinase (MKK6). J Biol Chem 1996;271:2886-2891.
84. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y: Jnk is involved in signal integration during costimulation of T lymphocytes. Cell 1994;77:727-736.
85. Avraham A, Jung S, Samuels Y, Seger R, Ben-Neriah Y: Co-stimulation-dependent activation of a JNK-kinase in T lymphocytes. Eur J Immunol 1998;28(8):2320-2330.
86. Cobb MH, Goldsmith EJ: How MAPKs are regulated. J Biol Chem 1995;270:14,843-14,846.
87. Ledbetter JA, Parsons M, Martin PJ, Hansen JA, Rabinovich PS, June CH: Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: Effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol 1986;137:3299-3305.
88. Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, Lindsten T, et al.: CD28 ligation in T cell activation: Evidence for two signal transduction pathways. Blood 1990;75:1531-1539.
89. Ward SG: CD28: A signalling perspective. Biochem J 1996;318:361-377.
90. Ledbetter JA, Linsley PS: CD28 receptor crosslinking induces tyrosine phosphorylation of PLC gamma 1. Adv Exp Med Biol 1992;323:23-27.
91. Ward SG, Wilson A, Turner L, Westwick J, Sansom DM: Inhibition of CD28-mediated T cell costimulation by the phosphoinositide 3-kinase inhibitor wortmannin. Eur J Immunol 1995;25: 526-532.
92. Hutchcroft JE, Bierer BE: Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins. Proc Natl Acad Sci USA 1994;91: 3260-3264.
93. Pages F, Ragueneau M, Rottapel R, Trunch A, Nunes J, Imbert J, et al.: Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994;369:327-329.
94. August A, Dupont B: Activation of src family kinase Ick following CD28 crosslinking in the Jurkat leukemic cell line. Biochem Biophys Res Commun 1994;199: 1466-1473.
95. Siliciano JD, Marrow TA, Desiderio SV: Itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2. Proc Natl Acad Sci USA 1992;89:11,194-11,198.
96. Heyeck SD, Berg LJ: Developmental regulation of a murine T cell-specific tyrosine kinase gene, Tsk. Proc Nat Acad Sci USA 1993;90:669-673.
97. Gibson S, Leung B, Squire JA, Hill A, Arima N, Goss P, et al.: Identification, cloning and characterization of a novel human T cell specific kinase located at the hematopoeitin complex on chromosome 5q. Blood 1993;82:1561-1572.
98. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279.
99. Mano H, Ishikama F, Nishida J, Hirai H, Takaku F: A novel protein-tyrosine kinase, tec, is preferentially expressed in liver. Oncogene 1990;5:1781-1786.
100. Haire RN, Ohta Y, Lewis JE, Fu SM, Kroisel P, Littman GW: TXK, a novel human tyrosine kinase expressed in T cells shares sequence homology with Tec family kinases and maps to chromosome 4p12. Hum Mol Genet 1994;3:897-901.
101. Tamagnone L, Lahtinen I, Mustonen T, Virtaneva K, Francis F, Muscatelli F, et al.: BMX, a novel nonreceptor tyrosine kinase of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene 1994;9:3683-3688.
102. Lemmon MA, Ferguson KM, Schlessinger J: PH domains: Diverse sequences with a common fold recruit signaling molecules to the cell surface. Cell 1996;85:621-624.
103. August A, Gibson S, Kawakami Y, Kawakami T, Mills GB, Dupont B: CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of tile Tee family kinase Itk/Emt in the human Jurkat leukemic T cell line. Proc Natl Acad Sci USA 1994;91:9347-9351.
104. Marengere LEM, Okkenhaug K, Clavrcul A, Couez D, Gibson S, Mills GB, et al.: The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28. J Immunol 1997;159:3220-3229.
105. Raab M, Cai Y-C, Bunnell SC, Heyeck SD, Berg LJ, Rudd CE: p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine ITK: Implications for T-cell costimulation. Proc Natl Acad Sci USA 1995;92:8891-8895.
106. Gibson S, August A, Branch D, Dupont B, Mills GB: Functional Ick is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/Itk. J Biol Chem 1996;271(12):7079-7083.
107. Heyeck SD, Wilcox HM, Bunnell SC, Berg LJ: Lck phosphorylates the activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity. J Biol Chem 1997;272(40):25,401-25,408.
108. Liao XC, Littman DR: Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 1995;3: 757-769.
109. Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR: Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med 1997;186(2):221-228.
110. Liu K-Q, Bunnell SC, Gurniak CB, Berg LJ: T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells. J Exp Med 1998;187(10):1721-1727.
111. Nunes J, Klasen S, Franco MD, Lipcey C, Mawas C, Bagnasco M, et al.: Signalling through CD28 T-cell activation pathway involves an inositol phospholipid-specific phospholipase C activity. Biochem J 1993;293:835-842.
112. Weiss A, Manger B, Imboden J: Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells. J Immunol 1986;137:819-825.
113. Van Lier RA, Brouwer M, De Groot ED, Kramer I, Aarden LA, Verhoeven AJ: T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways. Eur J Immunol 1991;21:1775-1778.
114. Nunes JA, Collette Y, Truneh A, Olive D, Cantrell DA: The role of p21ras in CD28 signal transduction: Triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras. J Exp Med 1994;180:1067-1076.
115. Nunes JA, Battifora M, Woodgett JR, Truneh A, Olive D, Cantrell D: CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the MAPKs: ERK2 and JUN kinases. Mol Immunol 1996;33(1):63-70.
116. ras. Eur J Immunol 1995;24:1044-1050.
117. Reedquist KA, Bos, JL: Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes. J Biol Chem 1998;273:4944-4949.
118. Bos JL, Franke B, M'Rabet L, Reedquist K, Zwartkruis F: Un search of a function for the Ras-like GTPase Rap1. FEBS Lett 1997;410(1):59-62.
119. Nunes JA, Truneh A, Olive D, Cantrell DA: Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. J Biol Chem 1996;271:1591-1598.
120. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, Bustelo XR: Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 1997;385:169-172.
121. Cantrell D: Lymphocyte signalling: A coordinating role for Vav? Curr Biol 1998;8:R535-R538.
122. Kaga S, Ragg S, Rogers KA, Ochi A: Activation of p21-CDC42/Rac-activated kinases by CD28 signaling:p21-activated kinase (PAK) and MEK kinase 1 (MEKK1) may mediate the interplay between CD3 and CD28 signals. J Immunol 1998:4182-4189.
123. Boucher L-M, Wiegmann K, Futterer A, Pfeffer K, Maehleidt T, Schutze S, et al.: CD28 signals through acidic sphingomyelinase. J Exp Med 1995;181:2059-2068.
124. Chan G, Ochi A: Sphingomyelinceramide turnover in CD28 costimulatory signaling. Eur J Immunol 1995;25:1999-2004.
125. Kapeller R, Cantley LC: Phosphatidylinositol 3-Kinase. Bioessays 1995;16:565-576.
126. Hutchcroft JE, Bierer BE: Signaling through CD28/CTLA-4 family receptors - Puzzling participation of phosphatidylinositol-3 kinase. J Immunol 1996;156:4071-4074.
127. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J: PDGF- and insulin-dependent pp70s6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-75.
128. Weng QP, Andrabi K, Kippel A, Kozlowski, MT, Williams LT, Avruch J: Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc Natl Acad Sci USA 1995;92:5744-5748.
129. Toker A, Meyer M, Reddy KK, Falck J, Aneja R, Aneja S, et al.: Activation of protein kinse C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5 P3. J Biol Chem 1994;269:32,358-32,367.
130. Moriya S, Kazlauskas A, Akimoto K, Hirai S-i, Mizuno K, Takenawa T, et al.: Platelet-derived growth factor activates protein kinase Cε through redundant and independent signaling pathways involving phospholipase Cγ or phosphatidylinositol 3-kinase. Prod Natl Acad Sci USA 1996;93:151-155.
131. Parry RV, Reif K, Smith G, Sansom DM, Hemmings BA, Ward SG: Ligation of the T cell co-stimulatory receptor CD28 activated the serine-threonin-protein kinase protein kinase B. Eur J Immunol 1997;27:2495-2501.
132. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al.: The protein kinase encoded by the AKT proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-Kinase. Cell 1995;81:727-736.
133. Burgering BMT, Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
134. Reif K, Burgering B, Cantrell DA: Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem 1997;272(22):14,426-14,433.
135. Cefai D, Cai Y-C, Hu H, Rudd C: CD28 co-stimulatory regimes differ in their dependence on phosphatidylinositol 3-kinase: Common cosignals induced by CD80 and CD86. Int Immunol 1996;8(10):1609-1616.
136. Ghiotto-Ragueneau M, Battifora M, Truneh A, Waterfield MD, Olive D: Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: Phosphatidylinositol 3-kinase association to CD28 and cytokine production. Eur J Immunol 1996;26:34-41.
137. Ueda Y, Levine BL, Huang ML, Freeman GJ, Nadler LM, June CH, et al.: Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Int Immunol 1995;7:957-966.
138. Truitt KE, Hicks CM, Imboden JB: Stimulation of CD28 Triggers an Association between CD28 and Phosphatidylinositol 3-kinase in Jurkat T cells. J Exp Med 1994;179:1071-1076.
139. Stein PH, Fraser JD, Weiss A: The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase. Mol Cell Biol 1994;14(5):3392-3402.
140. August A, Dupont B: CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase. Int Immunol 1994;6(5):769-774.
141. Reif K, Lucas S, Cantrell D: A negative role for phosphoinositide 3-kinase in T-cell antigen receptor function. Curr Biol 1997;7:285-293.
142. Cai Y-C, Cefai D, Schneider H, Raab M, Nabavi N, Rudd CE: Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity 1995;3:417-426.
143. Truitt KE, Shi J, Gibson S, Segal LG, Mills GB, Imboden JB: CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. J Immunol 1995;155:4702-4710.
144. Crooks MEC, Littman DR, Carter RH, Fearon DT, Weiss A, Stein PH: CD28-mediated costimulation in the absence of phosphalidylinositol 3-kinase association and activation. Mol Cell Biol 1995;15:6820-6828.
145. Pages F, Ragueneau M, Klasen S, Battifora M, Couez D, Sweet R, et al.: Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphotidylinositol 3-kinase association. J Biol Chem 1996;271:9403-9409.
146. Shimizu Y, van Seventer GA, Ennis E, Newman W, Horgan KJ, Shaw S: Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. J Exp Med 1992;175(2):577-582.
147. 1-integrin-mediated adhesion involves phosphatidylinositol 3-kinase. J Immunol 1996;156:883-886.
148. 1integrin-mediated cell adhesion by the Cb1 adapter protein. Curr Biol 1998;8:814-822.
149. Takai Y, Sasaki T, Tanaka K, Nakanishi H: Rho as a regulator of the cytoskeleton. Trends in Biochem Sci 1995;20:227-231.
150. Carrera A, Rodriguez-Borlado L, Martinez-Alonso C, Merida I: T cell receptor-associated alphaphosphatidylinositol 3-kinase becomes activated by T cell receptor cross-linking and requires pp56(Ick). J Biol Chem 1994;269:19,435-19,440.
151. Gimmi CD, Freeman GJ, Gribben GJ, Sugita K, Freeman AS, Morimoto C, et al.: B cell surface antigen B7/BB-1 provide a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Nat Acad Sci USA 1991;88:6575-6579.
152. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-730.
153. Fraser JD, Weiss A: Regulation of T-cell lymphokine gene transcription by tile accessory molecule CD28. Mol Cell Biol 1992;12(10):4357-4363.
154. Ghosh P, Tan T, Rice NR, Sica A, Young HA: The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc Nat Acad Sci USA 1993;90:1696-1700.
155. Wechsler AS, Gordon MC, Dendorfer U, Leclair KP: Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1994;153:2515-2523.
156. Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM: Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 1993;151:2601-2612.
157. Gerondakis S, Strasser A, Metcalf D, Grigoriadis G, Scheerlinck JY, Grumont RJ: Rel-deficient T cells exhibit defects in production of interleukin-3 and granulocytemacrophage colony-stimulating factor. Proc Natl Acad Sci USA 1996;93(8):3405-3409.
158. Butscher WG, Powers C, Olive M, Vinson C, Gardner K: Coordinate transactivation of the interleukin-2 CD28 response element by c-Rel and ATF-1/CREB2. J Biol Chem 1998;273(1):552-560.
159. Pai SY, Calvo V, Wood M, Bierer BE: Cross-linking CD28 leads to activation of 70-kDa S6 kinase. Eur J Immunol 194;24:2364-2368.
160. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM: Blockade of the CD28 co-stimulatory pathway: A means to induce tolerance. Curr Opinion Immunol 1994;6:797-807.
161. Harding FA, McArthur JG, Gross JA, Raulet D, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-609.
162. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, et al.: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177(1):165-173.
163. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, et al.: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 1995;3:87-98.
164. Yang XF, Weber GF, Cantor H: A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity 1997;7:629-639.
165. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al.: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
166. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89:11,102-11,105.
167. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of tile B7-CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994;84:3261-3282.
168. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L. Costimulation of minor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994;153: 421-428.
169. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
170. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al.: Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-1102.
171. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, et al.: CD28 B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995:4521-4524.
172. Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA-4Ig. Science 1994;265:1225-1227.
173. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al.: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707-718.
174. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, et al.: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-1155.
175. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, et al.: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 1996;156:1126-1131.
176. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, et al.: Distinct roles for BY-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96:2195-2203.
177. Gajewski TF. BY-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 1996:465-472.
178. Eck SC, Chang D, Wells AD, Turka LA: Differential down-regulation of CD28 by B7-1 and B7-2 engagement. Transplantation 1997;64(10): 1497-.
179. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke X-Y, Rennert PD, et al.: BY-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2:523-532.
180. Sigal LJ, Reiser H, Rock KL: The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J Immunol 1998;161:2740-2745.
181. Anderson DE, Ausubel LJ, Kreiger J, Hollsberg P, Freeman GJ, Hafler DA: Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones. J Immunol 1997;159:1669-1675.
182. Ollson C, Michaelsson E, Parra E, U. P, Lando PA, Dohlstein M: Biased dependency of CD80 versus CD86 in th induction of transcription factors regulating the human IL-2 promoter. Int Immunol 1998;10(4):499-506.
183. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, et al.: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995:97-105.
184. Natesan M, Razi-Wolf Z, Reiser H: Costimulation of IL-4 production by routine B7-1 and B7-2 molecules. J Immunol 1996:2783-2791.
185. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, et al.: CTLA4 mediated costimulation induces apoptosis of activated human T lymphocytes. Proc Natl Acad Sci USA 1994;92:811-815.
186. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465.
187. Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-2540.
188. Tivol EA, Schweitzer AN, Sharpe AH: Costimulation and autoimmunity. Curr Opinion Immunol 1996;8:822-830.
189. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tisssue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
190. Waterhouse P, Penninger JM, Timms E, Wakeman A, Shahinian A, Lee KP, et al.: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-988.
191. Chambers CA, Cado D, Truong T, Allison JP: Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 1997;94:9296-9301.
192. Chambers CA, Allison JP: The role of tyrosine phosphorylation and PTPIC in CLTA-4 signal transduction. Eur J Immunol 1996;26:3224-3229.
193. Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-2550.
194. Marengere LEM, Waterhouse P, Duncan GS, Mittrucker H-W, Feng G-S, Mak T: Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996;272:1170-1173.
195. Chambers CA, Sullivan TJ, Allison JP: Lymphoproliferation in CTLA-4 deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997;7:885-895.
196. Tivol EA, Boyd SD, McKeon S, Borriello F, Nickerson P, Strom TB, et al.: CTLA4Ig prevents lymphoproliferation and fatal mutiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997;158:5091-5094.
197. Waterhouse P, Bachmann MF, Penninger JM, Ohashi PS, Mak TW. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor transgenic CTLA-4 deficient mice. Eur J Immunol 1997;27:1887-1892.
198. Calvo CR, Amsen D, Kruisbeek AM. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated (ERK) and jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor ζ and ZAP70. J Exp Med 1997;186(10):1645-1653.